ZURA Zura Bio Ltd Insider Trading

AI Biotechnology LLC increases stake in unprofitable Zura Bio by 2,000,000 shares ($12.5M) to 6,552,725 shares (6.55M)

AI Biotechnology LLC, a 10% owner, purchased 2,000,000 shares at $6.25 on 2026-02-26, increasing its position by 43.9% from 4,552,725 to 6,552,725 shares. The transaction occurred when the stock was near its 52-week high ($7.00) and trading up 19.0% over 30 days and 92.6% over 90 days. This substantial $12.5M capital deployment into a company with negative net income of $-18.0M and a market cap of $439.6M suggests the insider is willing to deepen exposure despite near-term profitability challenges. The timing of this significant accumulation amid a strong recent price run warrants investor scrutiny of the company's near-term catalysts and whether management shares the confidence this substantial purchase signals.

Director Thiara Parvinder sells entire 1,001,633-share ZURA position ($2.7M) at $2.73; stock down 34.9% in 30 days

Thiara Parvinder's complete liquidation of her 1,001,633 shares at $2.73 on 2024-11-25 represents a full exit from her director position in ZURA. The sale occurs amid significant recent stock weakness—the stock has declined 34.9% over the prior 30 days and trades at $3.00, down 50.4% from its 52-week high of $6.05. Notably, this is Parvinder's second sale at ZURA within the past three months (her prior sale on 2024-09-11 saw the stock rise 50.4% over the following 30 days, making that trade poorly timed by the standard of subsequent price action). The company's fundamentals show a full-year net income of -$20,702,000 with a market cap of $195,880,590, indicating unprofitability. While Parvinder's cross-ticker sell track record shows a 100.00% well-timed rate with prior trades returning an average 24.3% over 30 days after her exits, this singular complete position liquidation—combined with the stock's recent deterioration and the company's negative earnings—warrants close monitoring of broader leadership sentiment and capital deployment constraints at ZURA.

Director Thiara Parvinder sold 3,800,000 shares of ZURA at $2.70 on 2024-09-11, reducing holdings by 79.1% to 1,001,633 shares; stock now at $3.70, -47.4% from 52-week high.

Thiara Parvinder executed a substantial open-market sale of 3,800,000 shares (3.80M shares) at $2.70 on 2024-09-11, liquidating 79.1% of her pre-transaction holdings of 4,801,633 shares and retaining only 1,001,633 shares. This represents a material reduction in her stake in an unprofitable company with net income of $-10,329,000.00 over its most recent full fiscal year. At the insider's prior sell at this same ticker on 2023-12-12, the 90-day outcome was -19.2%, classified as well-timed. The current price of $3.70 sits -47.4% below the 52-week high of $7.03, reflecting extended weakness since the transaction date. Investors should monitor whether the 90-day performance following this September 2024 sale replicates the prior timing pattern at ZURA.